Publications by authors named "Sven Adriaens"
Article Synopsis
- Paroxysmal nocturnal hemoglobinuria (PNH) is a rare blood disorder that can cause severe hemolysis and blood clots, and the new therapy pegcetacoplan aims to improve patient outcomes by targeting both types of hemolysis.
- The analysis of data from clinical studies showed that administering pegcetacoplan at a dose of 1080 mg twice weekly resulted in effective and stable levels in the body, along with significant improvements in blood biomarkers related to hemolysis within four weeks.
- Factors such as body weight and previous treatments influenced drug exposure and responses, but these effects were not significant enough to alter treatment effectiveness, supporting the approved dosage for optimal patient care.
